Dr Reddy’s is set to launch a semaglutide generic in India on Day 1 of patent expiry, offering both injectable and oral forms at significantly lower prices for diabetes and obesity patients.
Zydus Lifesciences launches Anyra, India’s first homegrown Aflibercept 2 mg biosimilar, offering affordable treatment for AMD, DR, DME, RVO, and mCNV, boosting access to advanced retinal care nationwide.
Lupin partners with Spektus Pharma to launch DeslaFlex in Canada, enhancing its CNS portfolio and offering patients a novel treatment option for Major Depressive Disorder.
.png)
Sanofi Healthcare India has expanded its Hyderabad Global Capability Centre, increasing capacity to 4,500 employees. Backed by a multi-hundred-million-dollar investment, the move strengthens India’s role in Sanofi’s global operations.
Biocon’s Q3 results show strong revenue and profit growth, led by Biosimilars and Generics. Strategic debt reduction and R&D investments position the company for robust FY27 performance.
.png)
Eli Lilly and Company has built a $1.5 billion inventory of its experimental weight-loss pill ahead of a key FDA decision. The move signals confidence in approval and a push to avoid supply shortages at launch.
Natco Pharma has received High Court approval to manufacture and export semaglutide, strengthening its entry into the global diabetes and obesity drug market and expanding its presence in metabolic disorder treatments.
Takeda Pharmaceutical has signed a major $1.7 billion deal with biotech firm Iambic, marking a fresh push to use AI drug discovery to speed up small-molecule research in cancer and gastrointestinal diseases.
Sun Pharmaceutical will invest Rs 500 crore to set up a drug manufacturing plant in Assam. The project will be rolled out in two phases and is expected to generate direct employment for over 500 people.
Lupin has launched Topiramate Extended-Release Capsules in the U.S. after receiving FDA approval for its ANDA, expanding access to treatments for epilepsy and migraine prevention.
.jpg)
, CDSCO.jpg)